Daily Judi: Monday, October 3, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
London-based GlobalData anticipates substantial growth in the wearable technology market, fueled largely by medical devices. The wearable technology industry accelerated during the COVID-19 pandemic, and GlobalData projects wearable tech will increase to a $156 billion industry by 2024, a 24.6% rise from 2020. (Medical Device Network)
Intranasal esketamine as a therapy for treatment-resistant depression was approved by the FDA in 2019. After three years of use, the LA Times examines its success. Dr. Philip O’Carroll, an Orange County neurologist, told the interviewer, “In the case of suicidal ideation, it brings people back from the brink.”
Following the announcement by pharmaceutical companies Eisai and Biogen of a successful phase 3 Alzheimer’s disease clinical trial for lecanemab, an anti-amyloid antibody, the NIH National Institute on Aging announced it's funding two trials to evaluate lecanemab’s effectiveness at treating Alzheimer’s disease and dementia. (NIH National Institute on Aging)
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
Our Culture
“I’ve been at the company over seven years, and it’s been really cool to watch the company grow and continue to increase how we help our clients. One of the many things I like about my job is that it’s not always the same thing every day, because each client is unique. It makes every day interesting.
Judi is a platform. It’s an adjudication tool, but it’s also more. It’s a whole collaborative workflow process tool. It works with DSMB, Eligibility, anything.”
–Stephen, Lead Engineer
About Judi
Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
